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Abstract
Background: Within the European Union the use of growth promoting agents in animal production is prohibited.
Illegal use of natural prohormones like dehydroepiandrosterone (DHEA) is hard to prove since prohormones are
strongly metabolized in vivo. In the present study, we investigated the feasibility of a novel effect-based approach
for monitoring abuse of DHEA. Changes in gene expression profiles were studied in livers of bull calves treated
orally (PO) or intramuscularly (IM) with 1000 mg DHEA versus two control groups, using bovine 44K DNA
microarrays. In contrast to controlled genomics studies, this work involved bovines purchased at the local market
on three different occasions with ages ranging from 6 to 14 months, thereby reflecting the real life inter-animal
variability due to differences in age, individual physiology, season and diet.
Results: As determined by principal component analysis (PCA), large differences in liver gene expression profiles
were observed between treated and control animals as well as between the two control groups. When comparing
the gene expression profiles of PO and IM treated animals to that of all control animals, the number of significantly
regulated genes (p-value <0.05 and a fold change >1.5) was 23 and 37 respectively. For IM and PO treated calves,
gene sets were generated of genes that were significantly regulated compared to one control group and validated
versus the other control group using Gene Set Enrichment Analysis (GSEA). This cross validation, showed that 6 out
of the 8 gene sets were significantly enriched in DHEA treated animals when compared to an ‘independent’
control group.
Conclusions: This study showed that identification and application of genomic biomarkers for screening of (pro)
hormone abuse in livestock production is substantially hampered by biological variation. On the other hand, it is
demonstrated that comparison of pre-defined gene sets versus the whole genome expression profile of an animal
allows to distinguish DHEA treatment effects from variations in gene expression due to inherent biological
variation. Therefore, DNA-microarray expression profiling together with statistical tools like GSEA represent a
promising approach to screen for (pro)hormone abuse in livestock production. However, a better insight in the
genomic variability of the control population is a prerequisite in order to define growth promoter specific gene
sets that can be used as robust biomarkers in daily practice.
Background
In the European Union the use of growth promoting
substances in livestock production is prohibited accord-
ing EC directive 96/22 [1]. To ensure compliance with
this legislation, requirements for monitoring are
described in EC directive 96/23 [2]. At national level,
legislations are implemented in residue monitoring pro-
grams regulating sampling of animal matrices and resi-
due analysis therein to guarantee fair trade, food safety
and public health. Residue analysis in livestock produc-
tion is in general based on chemical [3], immunochem-
ical or biological [4,5] screening methods followed by
mass spectrometry based confirmation methods.
Although this strategy seems to work for synthetic
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also occur naturally are used.
Abuse of naturally occurring (pro)hormones is hard to
prove since most of these substances are strongly meta-
bolized in vivo. Moreover, metabolites are not always
known or are present in levels not significantly different
from highly fluctuating endogenous levels. This makes
it difficult to prove fraudulent use based on quantifica-
tion of natural occurring compounds. Nowadays, it is
observed that misuse of growth promoters in cattle fat-
tening moves towards these natural steroids and steroid
esters. Moreover, inspections of livestock farms in The
Netherlands occasionally result in the finding of feed or
herbal additives and preparations containing so-called
prohormones. Prohormones are compounds that exhibit
limited or no hormonal action by themselves, however
they are direct precursors of active hormones and indir-
ectly affect natural hormone levels. Dehydroepiandros-
terone (DHEA) is such a prohormone and is the most
abundant occurring precursor of both androgens and
estrogens in humans [6,7]. It is claimed that orally
taken DHEA improves muscle strength and is therefore
illicitly used in sports to enhance performance and
appearance [8,9].
Looking for alternatives to support evidence of illegal
use of growth promoting substances, gene expression
analysis can be an attractive new approach. Several stu-
dies demonstrated changes in mRNA expression in
bovine tissues upon treatment with growth promoters
after performing real-time RT-PCR analysis on a limited
number of preselected genes [10-14]. Untargeted tran-
scriptomics approaches using microarrays allow gene
expression analysis of thousands of genes simulta-
neously as well as identification of (new) biomarkers for
screening [15,16]. Moreover, microarray data can pro-
vide mechanistic insights in cellular processes and path-
ways and can be used for classification of compounds
with the same mode of action (gene expression finger
prints) [17,18]. Comparative microarray analysis is
therefore in potential a promising screening tool for
growth promoter abuse and in particular for prohor-
mones of which the mode of action in cattle is some-
times unclear.
In recent work we used a metabolomics approach to
compare urine profiles of control and DHEA exposed
bovines [19]. This revealed several urinary steroid phase
I and phase II metabolites which are potential biomar-
kers for DHEA treatment. In the present study we
investigated the feasibility of monitoring prohormone
abuse at the mRNA level using liver tissue from the
same animal experiment. Gene expression profiles of
control and DHEA treated animals were compared to
determine differentially expressed genes and to identify
biomarkers for DHEA treatment.
Methods
Animals and treatment
Male Frisian bull calves were purchased at the local
market and housed for 2-3 weeks before the start of the
experiment. Treatment with DHEA was repeated in
three independent experiments using identical treatment
and sampling schedules. Each of the three experiments
consisted of two animals of which one was orally (PO)
treated with capsules containing 1000 mg DHEA
(Sigma, St. Louis, MO, USA) and the other was injected
intramuscularly (IM) with 1000 mg DHEA dissolved in
10 ml Miglyol 812 (Certa SA, Braine-l’Alleud, Belgium).
Administrations were performed seven times, at 24-hour
intervals. IM treated animals (n = 3, 262-355 kg) were
9-12 months old and PO treated animals (n = 3, 210-
410 kg) 8-13 months old. Control animals were included
in the first (n = 3, 6 months old, 153-174 kg) and third
(n = 4, 13-14 months old, 350-432 kg) experiment. An
overview of the experimental setup, age and weights of
the bovines is shown in table 1. Twenty-four hours after
the last treatment, the animals were sacrificed and liver
tissue was collected, snap-frozen in liquid nitrogen and
stored at -80°C until use. The experimental work was
approved by the Animal Ethics Committee of Ghent
University, Belgium, in accordance with local ethical
requirements.
Microarray analysis
Total RNA was extracted from tissues by homogeniza-
tion in Trizol (Invitrogen Life Technologies, Breda, The
Netherlands) and mixed with chloroform. The lysate
was centrifuged at 12000 × g for 15 minutes at 4°C and
the aqueous phase was transferred to be mixed with iso-
propanol which precipitates total RNA. After centrifu-
ging (10 minutes, 12000 xg at 4°C) the pellet was
washed with 75% ethanol and resuspended in RNase
Table 1 Experimental setup, age and weights of bovines
included in the DHEA animal treatment experiment.
Treatment Age Weight
Experiment #1 Intra muscular (IM 1) 9 months 290 kg
Oral (PO 1) 8 months 253 kg
Control (C 1-1) 6 months 174 kg
Control (C 1-2) 6 months 172 kg
Control (C 1-3) 6 months 153 kg
Experiment #2 Intra muscular (IM 2) 9 months 262 kg
Oral (PO 2) 8 months 210 kg
Experiment #3 Intra muscular (IM 3) 12 months 355 kg
Oral (PO 3) 13 months 410 kg
Control (C 3-1) 14 months 368 kg
Control (C 3-2) 14 months 386 kg
Control (C 3-3) 13 months 432 kg
Control (C 3-4) 13 months 350 kg
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according to the RNeasy mini kit protocol (Qiagen,
Westburg bv, Leusden, The Netherlands). After purifica-
tion, RNA integrity was determined spectroscopically
(Nanodrop technologies) and by gel electrophoresis.
Only RNA with A260/280 and A260/230 ratios above
1.8 was used for amplification. To generate fluores-
cently-labeled cRNA, the Agilent Low RNA Input Fluor-
escent Linear Amplification Kit (Agilent Technologies,
Palo Alto, CA, USA) was used according to the manu-
facturer’sp r o t o c o l .I ns h o r t ,1μg of total RNA was
reverse transcribed using T7 tagged oligo-dT primer
and labeled with Cy3 or Cy5 (Perkin Elmer/NEN Life
S c i e n c e s ,B o s t o n ,M A ,U S A ) .L i v e rR N A so ft h et r e a t e d
and control animals were individually labeled with Cy5
and RNA of all 7 control animals was pooled and
labeled with Cy3. After purification with the RNeasy
mini kit (Qiagen), label efficiency and yield were deter-
mined using a Nanodrop spectrophotometer (Nanodrop
technologies). A mixture of 1 μg of Cy3-labeled cRNA
and 1 μg of Cy5-labeled cRNA was hybridized onto a
44k bovine oligo microarray (Agilent Technologies),
using Agilent’s gene expression hybridization kit. Hybri-
dization was performed at 65°C for 17 hours in a hybri-
dization oven with rotation function (Agilent
Technologies). Upon hybridization, microarrays were
washed and dried according to the Agilent’s instructions
and fluorescence measurements were performed using
an Agilent Technologies G2565B microarray scanner.
Data processing
Fluorescence intensities were quantified using Feature
Extraction 8.5 software (Agilent Technologies). Data
were imported in GeneMaths XT 1.6 (Applied Maths,
St. Martens-Latem, Belgium) and signals below two
times background were excluded from further analysis.
Subsequently, the data was normalized as described by
Pellis et al. [20]. This normalization included correction
for the random error, with the median Cy3 signal for
each individual spot. Secondly, correction for the sys-
tematic error was performed with the median value of
the overall Cy5 signal. After normalization, principal
component analysis (PCA) was performed to visualize
differences between groups and t-test statistics were per-
formed to test for differential expression. Microarray
data was floored by adjusting low intensity spots to a
threshold value of 130, hereby reducing the number of
less reliable genes. Next, spot intensities were
2log trans-
formed and each gene was mean centered versus all
samples. Based on these
2log transformed data differen-
tially regulated genes were selected with a p-value <0.05
and a fold change >1.5 (>
2log 0.6) in each of the three
treatment replicates versus the average from the control
animals. Hierarchical clustering of the differentially
regulated genes was performed using Cluster and Tree-
view software [21]. Raw microarray data of the present
study have been submitted to ArrayExpress (available at:
http://www.ebi.ac.uk) and are stored under experiment
accession number A-MEXP-1810.
Gene set enrichment analysis (GSEA)
G e n es e te n r i c h m e n ta n a l y s i s( G S E A )i sat o o lt oi d e n -
tify and analyse the differential expression of biologically
relevant sets of genes that share common biological
functions [22]. Using GSEA, the differentially regulated
genes observed in DHEA treated animals versus one
control group (e.g. controls of experiment 1) were vali-
dated by evaluating this gene set by comparing the same
DHEA treated animals versus the other control group
(e.g. controls of experiment 3). Therefore, separate gene
sets were generated of the differentially expressed genes
of respectively IM treated animals (n = 3) and OS trea-
ted animals (n = 3) versus the controls of experiment 1
as well as the controls of experiment 3. For example,
the transcripts found significantly up-regulated when
comparing DHEA IM versus control group 1 were
included in the gene set “DHEA_IM_vs_CTR1_UP”.I na
similar way other gene sets were created for up- as well
as down-regulated genes. Next, GSEA ranks all genes on
the microarray on differential expression between
DHEA exposed and controls using signal to noise statis-
tics, resulting in a list with up-regulated genes at the
top and down-regulated genes at the lower end of the
list. Each of the pre-defined gene sets was tested against
this list and GSEA calculated whether the genes in the
gene set are randomly distributed, enriched at the top
or at the lower end of the ranked list. Permutations
were performed on gene sets and gene sets were consid-
ered significantly affected when the p-value was below
0.05 and the false discovery rate (FDR) below 0.25,
accordingly to GSEA recommendations [22].
Results and discussion
Principal component analysis (PCA) and selection of
differentially regulated genes
In the present study the potential strengths as well as
the pitfalls of microarray experiments using calves from
real-life practice were investigated. Three small animal
experiments were performed independently using bull
calves purchased at the local market. In this way the
experimental setup was taking into account the inherent
variability needed to investigate the usefulness of
bovine-specific microarrays as a screening tool for pro-
hormone abuse in veterinary control. For obvious ethical
reasons larger numbers of bovines treated with banned
substances could not be justified.
Upon microarray hybridization and data normaliza-
tion, unsupervised principal component analysis (PCA)
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profiles of control and treated animals. Figure 1 shows
the PCA-plot which is based on the three largest com-
ponents, representing 49.9% of the total variance.
Although there is variation in gene expression profiles
of livers of animals treated with DHEA, they are clearly
discriminated from those of the controls. However, large
differences are observed between the two control
groups, whereas the exposed animals (IM 1-3 and
PO 1-3) and the control animals of the first experiment
(CTR1) are separated along the x-axis while the control
bovines of experiment three( C T R 3 )a n dt h ee x p o s e d
bovines are mainly separated along the z-axis. Based
upon the outcome of this PCA, further analysis was
focused on comparison of the IM and PO treated ani-
mals versus either the total control population as well as
the two control groups separately.
Differentially regulated genes were selected using t-
test statistics. A p- v a l u e< 0 . 0 5a n dad i f f e r e n c eo fa t
least 1.5 ( >
2log0.6) fold change, versus the control aver-
age, observed in all three biological treatment replicates
(either IM or PO) were used as criteria for the selection
of differentially expressed genes. An overview of the dif-
ferentially regulated genes found in the IM and PO trea-
ted animals is shown in Figure 2. A total of 37 and 23
genes were found to be regulated in IM and PO treated
animals as compared to the total control group, respec-
tively. Only one of these genes (DMBT) was found dif-
ferentially expressed (down-regulated) in IM as well as
PO treated animals. A hierarchical cluster diagram of all
differentially regulated genes is presented in Figure 3.
Since many probes were spotted twice or more on the
microarray the 37 and 23 genes found regulated are
represented by 66 and 39 spots respectively. A detailed
description of all regulated genes is listed in Additional
file 1.
Of the 37 differentially expressed genes in response to
the IM DHEA treatment, 4 represented unidentified
transcripts and 7 were encoding for proteins with poorly
known or unknown function (LOC617652, LOC527553,
LOC515784, LOC617667, LOC515640, LOC497203 and
LOC521795). Among the 26 transcripts that encode for
Figure 1 Principal component analysis (PCA) of bovine liver gene expression profiles. PCA-plot showing the three principal components of
greatest variation which cover 22% (x-axis), 14% (y-axis) and 13% (z-axis) of the total variance respectively. Spheres in the PCA are representing
profiles of control animals of experiment 1 (green, C1 1-3), control animals of experiment 3 (red, C3 1-4), orally treated (blue, PO 1-3) and
intramuscular treated animals (yellow, IM 1-3) respectively.
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Page 4 of 9Figure 2 Venn diagram comparison of differentially expressed genes. Differentially expressed genes (p-value <0.05 and fold change >1.5
observed in each of the three treated animals) in liver of intramuscular (IM) and oral (PO) treated animals versus the mean of all controls, the
controls of experiment 1 (CTR 1) and experiment 3 (CTR 3). For each comparison the number of unique and shared genes are presented.
Figure 3 Hierarchical cluster analysis of significant regulated genes. Hierarchical cluster analysis (HCA) of genes with a p-value <0.05 and a
fold change >1.5 (fold changes calculated for each individual DHEA exposed animal versus the mean of all control animals) for (A)
intramuscularly and (B) orally treated animals. Based on
2log mean centered ratios, HCA was performed on genes only using average linkage
clustering. Colour scales are ranging from bright red to bright green which correspond with respectively up- or down-regulated genes.
Maximum brightness represents a fold change of ≥ 2(
2log mean centered ratios of ≤ -1 or ≥ 1).
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response and inflammatory processes. Of these latter
transcripts XBP1, MX1, LBP, SERPINA3, CCL24,
CARD14 and PIGR were found up-regulated and
ANKRD1, LYZ and DMBT were down-regulated. The
remaining transcripts are involved in various processes
like cell growth and proliferation (INHBE), formation of
tight-junctions (CLDN7), tumor suppression (DIRAS3),
cell proliferation and cell adhesion (CYR61) intra-
cellular signalling (JAG2) and cell-cell interactions
(LGALS4). Regarding metabolism, the GSTP1 gene was
found to be down regulated >1.6 fold in all IM treated
animals. GSTP1 mediates glutathione conjugation and
plays an important role in detoxification of xenobiotics
as well as in uptake and transport of numerous hydro-
phobic endogenous compounds like steroids [23] More-
over, it has been observed in mouse that the GSTP1
gene contains androgen receptor binding sites which
regulate GSTP1 activity in response to androgens [24].
Comparison of PO treated animals versus all control
animals revealed a total of 23 differentially expressed
genes of which 7 represent unidentified transcripts or
encoded for proteins with an unknown function. Again
a substantial number of the differentially regulated
genes are involved in immune response of which
LILRA5, THBS, CLEC6A and FUT1 were found up-
regulated and CCL14 and DBMT were down-regulated.
Other differentially regulated genes are involved in
peptidase inhibition (SERPINB8, WFDC1), G-protein
signalling (RGS5) and amino acid transport
(SLC6A14). Also regulated is the short/branched chain
acyl-CoA dehydrogenase (ACADSB) gene, a member
of the acyl-CoA dehydrogenase enzyme family which is
involved in fatty acid metabolism. This could point
towards regulation of fatty acid metabolism and is sup-
ported by a study in which DHEA administration to
rats showed significant regulation of genes involved in
fatty acid metabolism, including the very long chain
acyl-CoA gene which is also a member of the acyl-
CoA dehydrogenase enzyme family [25]. Overall it can
be stated that the majority of regulated genes are
involved in immune response for both PO as well as
IM treated animals which is in line with numerous
studies reporting the significant immune modulatory
properties of DHEA [26].
In principle the above listed genes are potential bio-
markers for DHEA treatment. On the one hand, we are
aware of the small number of animals used in this study
which hampers proper statistics and substantially
increases the chance of missing DHEA-responsive genes
or detecting false-positive genes. On the other hand,
combining and comparing the data of three indepen-
dently performed experiments will limit the risk of false-
positive genes considerably and results in identification
of only the most robustly regulated genes. Therefore, we
assessed whether the genes differentially expressed in
animals treated with DHEA via one administration
route versus animals of one control group would also be
affected when compared 1) to other control animals and
2) by the other administration route. To deal with these
issues we applied the statistics of gene set enrichment
analysis (GSEA). In this way statistical power could be
improved and regulated gene sets were tested for their
robustness.
Gene set enrichment analysis (GSEA)
For GSEA we used the genes found to be differentially
expressed when the exposed animals are compared with
the two control groups separately. For DHEA IM, 306
and 65 genes were differentially regulated versus CTR1
and CTR3, respectively, whereas for DHEA PO, 138 and
65 genes were regulated. As shown in Figure 2, a rela-
tively small number of genes was affected per treatment
in both comparisons versus CTR1 and comparisons ver-
sus CTR3. Apparently, only a low proportion of genes
showed a significant up-regulation or down-regulation
of 1.5 or more in both comparisons. GSEA was used as
a tool to discriminate DHEA treated animals from non-
treated animals on the basis of gene sets generated from
genes found to be differentially regulated (Figure 2).
Gene sets were compared to the whole experimental
dataset and GSEA calculated whether genes within a
gene set are randomly distributed, enriched at the top
or at the bottom of the ranked list [22]. The advantage
of this GSEA approach is that no cut-off is used for
determination of differentially regulated genes. Using
the whole experimental data set makes that alterations
are viewed for as a group of genes instead for individual
genes. Gene sets can be significantly affected while
changes in expression of individual genes are relatively
subtle. For example, the transcripts found to be signifi-
cantly up-regulated when comparing DHEA IM versus
control group 3 (Figure 4A) were included in the gene
set ‘DHEA_IM_vs_CTR3_UP’. GSEA analysis, using this
gene set, showed that the genes where highly enriched
in DHEA IM treated animals when comparing versus
the CTR1-group (Figure 4B). As shown in Figure 4C,
most of the genes are distinctly up-regulated in DHEA
IM treated animals, although also variation in gene
expression of the individual animals is observed. In a
similar way, the other gene sets were compared versus
the other ‘independent’ control group and results are
summarized in Table 2. This cross validation showed
that 6 out of 8 gene sets were significantly enriched
(p-value <0.05 and FDR < 0.25) when DHEA treated
animals were compared versus an ‘independent’ control
group. Moreover, gene sets generated on the basis
of DHEA IM treated animals showed significant
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In total 12 out of 16 gene set comparisons showed sig-
nificant enrichment, suggesting an overlap in gene
expression profiles from IM and PO treated animals
which most likely include genes that are differentially
expressed irrespective of the manner of DHEA
administration.
Although in vivo transcriptomics data of DHEA in
liver is limited [25,27], Depreter et al. identified 13
genes which were found to be up-regulated in rat liver
[25]. GSEA analysis showed significant enrichment of
this gene set in DHEA IM and PO treated animals
when these were compared with the controls of experi-
ment 1 (Table 2). These results illustrate that GSEA is a
powerful approach for comparative analysis of gene
expression data obtained in different settings.
Controlled experiments with bovines have resulted in
the identification of genomics based biomarkers which
potentially can be used for screening for hormones
[10-14,28]. However, when examining bovines from
real-life practice, one is dealing with biological variation
like age, genetic background, environment, nutrition and
disease history. In the current study, this biological var-
iation was deliberately included and was mainly reflected
Figure 4 Overview of the GSEA method applied. (A) Heat map of the gene set ‘DHEA_IM_vs_CTR3’ containing all genes found significantly
up-regulated (> 1.5 fold and p-value <0.05) when comparing DHEA IM treated animals versus the control population of experiment 3. Colours
range from dark red to dark blue representing respectively the highest and lowest expression of a gene. (B) This gene set was compared to the
ranked list of the total microarray expression data set of DHEA IM treated and CTR1 animals showing a significant (p-value 0.000 and FDR of
0.000) enrichment of genes in DHEA IM treated animals when compared to the control group of experiment 1. (C) Heat map displaying the
genes of gene set ‘DHEA_IM_vs_CTR3’ in DHEAIM and CTR1 animals.
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the control populations tested. The two control groups
in this study showed substantial age differences i.e. the
animals in the CTR1, CTR3 and DHEA-treated groups
are 6 months, 13-14 months and 8-13 months in age,
respectively. Nevertheless, for the DHEA IM and PO
treated animals, sets of respectively 37 and 23 genes
were found differentially expressed when compared to
all controls using standard statistics. These two groups
of genes are specific for IM and PO treatment, respec-
tively, and independent from biological factors like age.
However, GSEA results showed a correlation between
gene expression profiles of IM and PO treated animals,
suggesting that there are also effects independent from
the route of administration. This is in line with our ear-
lier performed metabolomics study showing large simila-
rities in urine metabolite profiles of IM and PO treated
animals as well as metabolites specific for the route of
administration [19].
Hence, for application of transcriptomics based
screening of bovines for (pro)hormones in practice, the
treatment effect should be filtered out from differences
in gene expression due to inherent biological variation.
Here it was shown that microarray gene expression pro-
filing in combination with statistical methods like GSEA
are able to distinguish gene expression profiles of
DHEA-treated animals from non-treated control ani-
mals. It should be noted that this experiment comprised
small numbers of animals and follow up experiments
are required to gain statistical power and to obtain a
better description of DHEA specific gene sets. Further-
more, the behaviour of such a growth promoter specific
gene set should be studied in a broad spectrum of
untreated control animals from daily practice, to assure
the robustness of the gene set. This underlines the need
to obtain more liver gene expression profiles of control
animals from slaughterhouses.
Conclusion
The present study showed that identification of genomic
biomarkers for DHEA treatment in cattle is hampered
by the large biological variability as compared to geno-
mics experiments with inbred strains of rodents under
well-defined laboratory conditions. However, gene
Table 2 Significance of gene set regulation after GSEA analysis.
DHEA IM group compared to CTR1 DHEA IM group compared to CTR3
Name gene set # Genes p-value FDR p-value FDR
DHEA_IM_vs_CTR1_up 98 - - 0.000* 0.000
DHEA_IM_vs_CTR1_down 208 - - 0.000* 0.071
DHEA_IM_vs_CTR3_up 46 0.000* 0.000 - -
DHEA_IM_vs_CTR3_down 19 0.826 0.823 - -
DHEA_PO_vs_CTR1_up 65 0.000* 0.000 0.751 0.887
DHEA_PO_vs_CTR1_down 73 0.000* 0.000 0.861 0.899
DHEA_PO_vs_CTR3_up 31 0.032* 0.073 0.000* 0.000
DHEA_PO_vs_CTR3_down 34 0.312 0.413 0.000* 0.000
Depreter_et_al_up 11 0.015* 0.031 0.381 0.657
DHEA PO group compared to CTR1 DHEA PO group compared to CTR3
Name gene set # Genes p-value FDR p-value FDR
DHEA_PO_vs_CTR1_up 65 - - 0.000* 0.000
DHEA_PO_vs_CTR1_down 73 - - 0.007* 0.002
DHEA_PO_vs_CTR3_up 31 0.173 0.292 - -
DHEA_PO_vs_CTR3_down 34 0.015* 0.014 - -
DHEA_IM_vs_CTR1_up 98 0.000* 0.000 0.000 0.479
DHEA_IM_vs_CTR1_down 208 0.000* 0.000 0.000* 0.000
DHEA_IM_vs_CTR3_up 46 0.706 0.738 0.000* 0.000
DHEA_IM_vs_CTR3_down 19 0.009* 0.006 0.002* 0.001
Depreter_et_al_up 11 0.029* 0.030 0.887 1.000
* Significantly regulated gene set.
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combination with predefined gene sets and statistical
methods like GSEA showed to be a promising approach
to screen for (pro)hormone abuse in livestock produc-
tion. For application in practice however, a better geno-
mic description of the control population as well as
growth promoter specific gene set are needed.
Additional material
Additional file 1: Differentially expressed genes. Tables of
differentially expressed genes
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